ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Variability In Plasma Donor-derived Cell-free DNA Levels With CLAD More Than 5-years After Lung Transplantation: Pilot Data

D. Levine1, D. Ross2

1Department of Medicine, University of Texas, San Antonio, San Antonio, TX, 2Natera, Inc., Ausin, TX

Meeting: 2022 American Transplant Congress

Abstract number: 9078

Keywords: Graft survival, Lung transplantation

Topic: Clinical Science » Lung » 64 - Lung: All Topics

Session Information

Session Name: Lung Transplantation

Session Type: Poster Abstract

Date: Monday, June 6, 2022

Session Time: 7:00pm-8:00pm

 Presentation Time: 7:00pm-8:00pm

Location: Hynes Halls C & D

*Purpose: Donor-derived cell-free DNA (dd-cfDNA) has been clinically validated for detection of acute rejection (AR) in lung transplant (LT) although studies have typically focused on the period soon after LT. Yang et al. (2021) reported median nadir dd-cfDNA in stable patients of 0.21% at 4-mos post-LT, with an increase to 0.60-0.68% at 18-24 months. Only limited data has been reported regarding dd-cfDNA plasma levels in long term survivors.

*Methods: A single-center, cross-sectional cohort study of LT recipients (LTR) with chronic lung allograft dysfunction (CLAD) ≥5-years post-LT was performed. Plasma dd-cfDNA fractions (dd-cfDNA%; the Prospera™test; Natera, Inc.) and quantity (dd-cfDNA copies/mL) were assessed. LTR clinical status was categorized as either Complicated (C-CLAD) or Uncomplicated (U-CLAD). C-CLAD was defined as clinical presence of concurrent allograft infection, antibody-mediated rejection (AMR), or chronic severe GER / aspiration. Data is presented as median (25-75% IQR) and cohorts analyzed by Mann-Whitney-U test (p<0.05).

*Results: The 12 LTR (bilateral=11, unilateral=1) in this cohort were comprised of: CF (2), IPF (4), COPD / bronchiectasis (4), Re-LT (1), IPAH (1). At the time of dd-cfDNA assessment the median time after LT for native lung disease was 2,149 days (1899-2920). The C-CLAD cohort was determined on the basis of chronic aspiration (1), AMR (3), infection (1). Median dd-cfDNA (%) for the C-CLAD cohort (N=5) was 1.790% (IQR: 1.035-2.285), which was significantly elevated compared to the U-CLAD cohort (N=7; 0.490%; 0.280-0.880) (p=0.0178) (Figure 1A). dd-cfDNA quantity was also elevated in the C-CLAD cohort (43.20 cp/mL; 27.91-89.28) versus U-CLAD cohort (19.63 cp/mL; 8.15-27.90) (p=0.048) (Figure 1B).

*Conclusions: Cross-sectional analysis of patients with CLAD more than 5-years after LT shows significant variability in both dd-cfDNA fraction and quantity (cp/mL) based on the presence or absence of allograft co-morbidities (C-CLAD). By contrast, the dd-cfDNA fraction in U-CLAD appears similar to previously reported values for stable and healthy LTR.

We speculate that the presence of elevated dd-cfDNA in CLAD may heighten a clinical suspicion for co-morbidities that may respond to additional forms of therapy. Additionally, quantification of dd-cfDNA (cp/mL) may offer additional insights and precision for longitudinal assessment accompanying treatment algorithms.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Levine D, Ross D. Variability In Plasma Donor-derived Cell-free DNA Levels With CLAD More Than 5-years After Lung Transplantation: Pilot Data [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/variability-in-plasma-donor-derived-cell-free-dna-levels-with-clad-more-than-5-years-after-lung-transplantation-pilot-data/. Accessed May 30, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences